Baxter International (BAX) UBS Global Healthcare Conference summary

Reflections on transformation and challenges

• Significant transformation over the past years, including business separations and verticalization, has been both a challenge and a catalyst for future success.

• Opportunities identified in accelerating growth, improving cash flow, and enhancing operational execution.

• The company has focused on restoring supply chain stability, particularly after the North Cove incident.

Strategic priorities and financial outlook

• Key priorities include accelerating growth, expanding margins, and improving cash efficiency.

• Resource allocation is shifting toward higher-return projects, with a focus on operational consistency.

• 2024 guidance reflects a $200 million top-line impact from North Cove, with operating income adjustments detailed for 2024 and 2025.

• 2025 targets include 4%-5% sales growth, driven by both volume and pricing, with new product launches in pumps, injectables, and HST.

Product and market dynamics

• Novum and Spectrum pumps are driving share gains, with robust demand and competitive wins.

• Pharmaceutical injectables and new HST launches are expected to contribute to growth in 2025 and beyond.

• HST order visibility is strong, with easier comps and growing order books supporting momentum.

• GPO contract renegotiations are largely complete, with ongoing IDN negotiations and improved pricing flexibility.